Pelabresib,Ruxolitinib
morphosys
['$mor', 'morphosys']
morphosys presents multiple analyses of the manifest phase 2 trial investigating the potential of pelabresib in the treatment of myelofibrosis at eha 2022 $mor 
Run by investors, for investors.

Real-time:
PRs
Gov. contract awards
Earnings
M&As
FDA approvals
Insider trades
SEC filings
And more

Not investment advice